BioBridgeX
Log inCompare quotes
Indication

Ophthalmology CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing an ophthalmology program means finding CROs and CDMOs that understand the eye as a compartment: intravitreal, topical, and suprachoroidal delivery, ocular PK, species-specific retinal models, and endpoints like BCVA and IOP. It spans discovery, IND-enabling tox, clinical ophthalmic trials, and sterile injectable fill-finish. On BioBridgeX, buyers source and compare qualified suppliers free, as the neutral marketplace, then contract directly with the supplier they choose.

Ophthalmology CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Ophthalmology CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What kind of CRO work does an ophthalmology program need?

Ophthalmology outsourcing is shaped by one fact: the eye is a small, immune-privileged, hard-to-reach compartment, and almost every service has an ocular-specific version. A general tox CRO can dose a rat orally; far fewer can deliver a drug intravitreally into a rabbit eye, run an ocular PK study that samples vitreous, aqueous, and retina-choroid separately, and read out ocular irritation by a validated scoring scale. So the first thing you are buying in this indication is not generic capability, it is hands that know the eye.

On the discovery and preclinical side, the work runs through in vitro models (retinal pigment epithelium cultures, photoreceptor and ganglion-cell systems, corneal epithelial models) and into the disease models that matter for your indication: laser-induced choroidal neovascularization for wet AMD, oxygen-induced retinopathy for retinopathy of prematurity and DME-adjacent angiogenesis, ocular hypertension and optic-nerve-crush models for glaucoma, and dry-eye and uveitis models for surface and inflammatory disease. Delivery route drives a lot of this. An intravitreal biologic, a topical small molecule, a suprachoroidal injection, and a gene therapy delivered subretinally each need different formulation work, different ocular PK, and different safety readouts. Larger eyes matter for translation, which is why non-human-primate work shows up in retinal programs more than in most other therapeutic areas.

IND-enabling and clinical work carry the same ocular fingerprint. GLP ocular toxicology has to handle local tolerance, intraocular pressure, slit-lamp and fundus examination, electroretinography, and ocular histopathology read by a pathologist who knows ophthalmic tissue. On the clinical side you need a CRO with ophthalmology site networks and the reading-center relationships that ophthalmology trials live on: standardized BCVA refraction (ETDRS letters), OCT-based anatomical endpoints like central subfield thickness, fundus photography and fluorescein angiography grading, and IOP measurement done consistently across sites. For injectable products, the manufacturing side needs a CDMO that can run aseptic, sterile fill-finish for intravitreal use, where particulate control and endotoxin limits are tighter than for most other routes.

How do you choose a CRO for ophthalmology?

The logo matters less than whether the specific team has run your kind of eye program before. A group with deep wet-AMD experience may have never touched a glaucoma IOP study or a subretinal gene-therapy delivery, and ocular dosing technique is genuinely a skill that varies between hands. Put two or three suppliers against the same written scope and work the checklist below. Ask for indication-specific case studies, the names and ophthalmology background of the people who would actually run the study, and reference contacts you can call.

  • Therapeutic-area experience: confirm real ophthalmology depth in your exact indication (wet AMD, DME, glaucoma, dry eye, uveitis, inherited retinal disease) and your delivery route (intravitreal, topical, suprachoroidal, subretinal), not just general preclinical or clinical work.
  • Relevant models and ocular technique: check they run the disease models you need (laser CNV, oxygen-induced retinopathy, ocular hypertension, dry-eye) and that staff are trained in ocular dosing, plus access to the right species, including non-human primates where retinal translation requires it.
  • Ocular endpoints and instrumentation: for clinical work, confirm standardized BCVA/ETDRS refraction, OCT reading-center relationships, fundus photography and angiography grading, and consistent IOP measurement; for preclinical, confirm ERG, slit-lamp, fundoscopy, and ophthalmic histopathology.
  • Regulatory track record: ask about INDs filed and ophthalmology programs taken through FDA or EMA, GLP status for the safety work, and familiarity with ocular-specific guidance and CMC expectations for intraocular products.
  • Data quality and traceability: documented SOPs, masked grading where endpoints are subjective, audit-ready raw data, and reading-center standardization so an OCT or angiography readout means the same thing across sites and over time.
  • Capacity and timeline: ocular specialists are a smaller pool and can be booked solid, so confirm the real queue, NHP availability if needed, and honest turnaround before you commit.
  • Manufacturing fit (if applicable): for injectables, a CDMO with aseptic sterile fill-finish for ophthalmic use, particulate and endotoxin control suited to intravitreal delivery, and container-closure experience for prefilled syringes or vials.

Frequently asked questions

What makes an ophthalmology CRO different from a general preclinical or clinical CRO?
The eye needs specialized handling at almost every step. Ophthalmology CROs are trained in ocular dosing routes (intravitreal, topical, suprachoroidal, subretinal), run eye-specific disease models, and own the instrumentation that ocular work depends on: ERG, slit-lamp and fundus exam, OCT, fluorescein angiography, and tonometry for IOP. On the clinical side they bring ophthalmology site networks and reading-center relationships, plus staff who can do standardized BCVA refraction. A capable general CRO can run your chemistry or your basic tox, but the ocular-specific portions (local tolerance, ocular PK, masked endpoint grading) usually need a group that does eyes routinely.
Which preclinical models are used for ophthalmology indications?
It depends on the disease. Wet AMD and other neovascular conditions typically use the laser-induced choroidal neovascularization model. Angiogenesis and retinopathy work uses oxygen-induced retinopathy. Glaucoma uses ocular hypertension and optic-nerve-crush models to study IOP and neuroprotection. Dry eye and ocular surface programs use induced dry-eye models, and inflammatory programs use uveitis models. Species choice matters a lot here: rabbits are common for delivery and ocular PK because of eye size, and non-human primates appear in retinal programs where the macula and eye dimensions are closer to human, which improves translation of intravitreal and subretinal work.
What endpoints do ophthalmology clinical trials measure?
Most programs combine a functional endpoint and an anatomical one. Best-corrected visual acuity (BCVA), measured in ETDRS letters under standardized refraction, is the workhorse functional endpoint for retinal disease. OCT-derived anatomical measures, especially central subfield thickness, track fluid and structural change. Glaucoma programs center on intraocular pressure. Fundus photography, fluorescein and OCT angiography, and visual-field testing add supporting data. Because several of these endpoints are graded subjectively, ophthalmology trials lean heavily on independent reading centers and masked grading so the readouts stay consistent across sites and credible to regulators.
Do intravitreal and ocular injectable products need a specialized CDMO?
Yes. Intraocular products are sterile injectables held to tight standards, and the eye is unforgiving of particulates and endotoxin. You want a CDMO with aseptic, sterile fill-finish experience specifically for ophthalmic use, appropriate particulate and endotoxin control, and container-closure experience for the format you are using, whether prefilled syringes or vials. For gene and cell therapies delivered to the eye, add the relevant viral-vector or advanced-therapy manufacturing capability. Treat sterile ophthalmic fill-finish as a specialist capability rather than something any injectable CDMO can do without ocular-specific controls.
How long does ophthalmology drug development outsourcing take?
There is no single number, because it depends on stage, indication, and delivery route. A focused preclinical efficacy study in an established model can run a few months; a full GLP ocular tox package with ERG, histopathology, and local tolerance takes longer and is gated by species availability, with non-human-primate slots often the limiting factor. Clinical ophthalmology trials are paced by the endpoint: anatomical OCT signals can read earlier, while BCVA-based efficacy usually needs longer follow-up. Scope each piece (efficacy model, IND-enabling tox, clinical phase, manufacturing) as a separate milestone with its own go/no-go gate so the timeline and spend stay under control.
How does BioBridgeX work for sourcing ophthalmology suppliers, and what does it cost the buyer?
BioBridgeX is free for buyers. You describe the ophthalmology work you need, get matched with qualified CRO and CDMO suppliers, and compare them side by side. BioBridgeX acts as the neutral marketplace, so you compare quotes and contract directly with each supplier you choose, in one place, even when several suppliers are involved across discovery, IND-enabling, clinical, and manufacturing. Suppliers pay a flat 2% fee, which keeps the matching neutral rather than pay-to-rank. The platform covers all indications and modalities, so an ophthalmology program that also needs, for example, viral-vector manufacturing can be sourced in the same place.

Source Ophthalmology work with one contract

Compare transparent quotes from qualified Ophthalmology CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes